. Author manuscript; available in PMC: 2018 Apr 1.

Published in final edited form as: Hematol Oncol Clin North Am. 2017 Apr;31(2):317–334. doi: 10.1016/j.hoc.2016.11.006

TABLE 9.

Treatment of LyP

1^st Line	Active non-treatment Topical corticosteroids Class I-III for trunk and extremities; Class IV, V for face, genitals and axillae Phototherapy Methotrexate, 5–25mg/week^*
2^nd Line	Topical tacrolimus Topical nitrogen mustard Topical retinoids (bexarotene) Topical carmustine
3^rd Line	Radiotherapy^* Imiquimod 5% cream Interferon-a, Interferon-g Brentuximab vendotin (anti-CD30 monoclonal antibody)^** Antiobiotics: tetracyclines, penicillin, erythromycin Sulfones Surgical excision^*

Generally accepted regimens include starting doses 7.5–12.5mg per week, increasing as tolerated every 8–12 weeks until clear up to 25mg per week. Once control has been maintained for 8–12 weeks with no new lesions, the dose is titrated down in a similar fashion to the lowest dose attainable without flares.

^**

For larger, refractory and persistent lesions

^***

For multifocal disease

Adapted from: Klein, RS, Singer E, Junkins-Hopkins JM, Vittorio CC, Rook AH, Kim EJ. “141: Lymphomatoid Papulosis.” Treatment of skin disease: Comprehensive therapeutic strategies. By Lebwohl, M. G., Heymann, W., Berth-Jones, J., & Coulson, I. 4^th ed. Edinburgh: Saunders. 2014. 430–434, with permission.